Bluebird bio details plans to file three blockbusters
Biotech looks to take on Novartis, Gilead, and Juno in CAR-T
Biotech looks to take on Novartis, Gilead, and Juno in CAR-T
Regulator agrees to restart phase 1 trial of UCART 123
Juno has hopes pinned on JCAR017
Biotech plans pivotal trial next year.
Kite to start filing data for KTE-C19 with US regulator.
Doubts over Juno CAR-T therapy after two more trial deaths.
T-cell trial will include controversial chemo agent fludarabine.
Novartis may have concerns about commercial prospects, says expert.